2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …

N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Kidney and heart failure outcomes associated with SGLT2 inhibitor use

AB van der Aart-van der Beek, RA de Boer… - Nature Reviews …, 2022 - nature.com
Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …

Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape

CW Mende - Advances in therapy, 2022 - Springer
There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …

Hypertension management in patients with cardiovascular comorbidities

L Lauder, F Mahfoud, M Azizi, DL Bhatt… - European Heart …, 2023 - academic.oup.com
Arterial hypertension is a leading cause of death globally. Due to ageing, the rising
incidence of obesity, and socioeconomic and environmental changes, its incidence …

The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension

HL Kim, EM Lee, SY Ahn, K Kim, HC Kim, JH Kim… - Clinical …, 2023 - Springer
Hypertension is the leading cause of death in human being, which shows high prevalence
and associated complications that increase the mortality and morbidity. Controlling blood …

A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors

T Sen, HJL Heerspink - Cell metabolism, 2021 - cell.com
Sodium glucose co-transporter (SGLT) 2 inhibitors reduce the risk of kidney failure in
patients with and without type 2 diabetes (T2D). Although the precise underlying …

Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure

M Böhm, SD Anker, J Butler, G Filippatos… - Journal of the American …, 2021 - jacc.org
Background Empagliflozin reduces the risk of cardiovascular death or heart failure (HF)
hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood …

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, N Staplin, KJ Mayne, C Wanner… - The Lancet Diabetes & …, 2024 - thelancet.com
Summary Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk
of the primary composite outcome of kidney disease progression or cardiovascular death in …

[PDF][PDF] Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease

KJ Mayne, N Staplin, DF Keane… - Journal of the …, 2024 - journals.lww.com
BACKGROUND: Chronic kidney disease (CKD) is associated with fluid excess which can be
estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co …

Are SGLT2 inhibitors new hypertension drugs?

K Kario, KC Ferdinand, W Vongpatanasin - Circulation, 2021 - Am Heart Assoc
EDITORIAL for this finding is unclear, but this population is more likely to be older, to be
Black, and to be prescribed calcium channel blockers or β-blockers. It is possible that a lack …